NEOVASC INC. NAMED A 2011 TOP 50 COMPANY BY TSX VENTURE EXCHANGE
–Selected for 2011 TSX Venture 50 Award in Technology & Life Sciences–
TSX Venture Exchange: NVC
companies identified from the more than 2,000 firms listed on the TSX Venture Exchange. Neovasc
was selected as one of 10 recipients in the Technology & Life Sciences sector.
“The TSX Venture Exchange includes some of the most dynamic young
companies in
of being among the 50 best performing listed companies,” said Neovasc CEO
for continued growth this year, as we advance our Reducer(TM) product for refractory angina towards commercialization and continue to
expand our PeriPatch(TM) implantable tissue business for specialized cardiac, vascular and surgical applications.”
The TSX Venture 50((R)) are the top 10 companies listed on the TSX Venture Exchange, in each of
five major industry sectors – mining, oil & gas, technology & life sciences, diversified industries
and clean technology – based on a ranking formula with equal weighting given to return on
investment, market cap growth, trading volume and analyst coverage. All data was as of
31, 2010
For more information visit http://tsxventure.com/
Neovasc was recognized as a TSX Venture 50((R)) company in 2011. TSX Venture 50 is a trade-mark of TSX Inc. and is used under license.
About Neovasc Inc.
Neovasc Inc. is a specialty vascular device company that develops,
manufactures and markets medical devices for the rapidly growing
vascular and surgical marketplace. The company’s current products include the Neovasc Reducer(TM), a novel product in development to treat refractory angina, as well as
a line of advanced biological tissue technologies that are used to enhance
surgical outcomes and as key components in a variety of third-party medical products. For more
information, visit: www.neovasc.com .
Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words “anticipates,“ “believes,“ “may,“ “continues,“ “estimates,“ “expects,“and “will” and words of similar import, constitute “forward-looking statements“ within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual results, events or developments to be
materially different from any future results, events or developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following: general
economic and business conditions, both nationally and in the regions in
which the Company operates; history of losses and lack of and
uncertainty of revenues, ability to obtain required financing, receipt
of regulatory approval of product candidates, ability to properly
integrate newly acquired businesses, technology changes; competition;
changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations;
liability and other claims asserted against the Company; and other
factors referenced in the Company‘s filings with Canadian securities regulators. Although the Company
believes that expectations conveyed by the forward-looking statements
are reasonable based on the information available to it on the date
such statements were made, no assurances can be given as to the future
results, approvals or achievements. Given these uncertainties, readers
are cautioned not to place undue reliance on such forward-looking
statements. The Company does not assume the obligation to update any
forward-looking statements except as otherwise required by applicable
law.
SOURCE Neovasc Inc.